treatment

Number of resources: 98

Diabetic foot--what can we learn from leprosy? Legacy of Dr Paul W. Brand.

Risk of developing disability in pre and post-multidrug therapy treatment among multibacillary leprosy: Agra MB Cohort study.

Hansen's Disease (Leprosy): Current and Future Pharmacotherapy and Treatment of Disease-Related Immunologic Reactions.

Deep venous thrombosis and pulmonary embolism secondary to co-administration of thalidomide and oral corticosteroid in a patient with leprosy.

Electromyography function, disability degree, and pain in leprosy patients undergoing neural mobilization treatment.

The effect of systemic corticosteroid therapy on the expression of toll-like receptor 2 and toll-like receptor 4 in the cutaneous lesions of leprosy Type 1 reactions.

Deciphering the mystery of thalidomide teratogenicity.

Development of lepromatous leprosy following etanercept treatment for arthritis.

Recurrent disseminated intravascular coagulation caused by intermittent dosing of rifampin.

Hypersensitivity Reactions to Dapsone: A Systematic Review.

Inhibition of angiogenesis as a new therapeutic target in the treatment of lepromatous leprosy.

Leprosy in china.

Lun ZR, Zhu XQ, Yang TB. Leprosy in china. Lancet Infect Dis. 2012;12(1):11.

Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up.

Azathioprine as a steroid sparing agent in leprosy type 2 reactions: report of nine cases.

Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers

Seagrass as a potential source of natural antioxidant and anti-inflammatory agents.

Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis

Advances and hurdles on the way toward a leprosy vaccine.

treatment

Diabetic foot--what can we learn from leprosy? Legacy of Dr Paul W. Brand.

Risk of developing disability in pre and post-multidrug therapy treatment among multibacillary leprosy: Agra MB Cohort study.

Hansen's Disease (Leprosy): Current and Future Pharmacotherapy and Treatment of Disease-Related Immunologic Reactions.

Deep venous thrombosis and pulmonary embolism secondary to co-administration of thalidomide and oral corticosteroid in a patient with leprosy.

Electromyography function, disability degree, and pain in leprosy patients undergoing neural mobilization treatment.

The effect of systemic corticosteroid therapy on the expression of toll-like receptor 2 and toll-like receptor 4 in the cutaneous lesions of leprosy Type 1 reactions.

Deciphering the mystery of thalidomide teratogenicity.

Development of lepromatous leprosy following etanercept treatment for arthritis.

Recurrent disseminated intravascular coagulation caused by intermittent dosing of rifampin.

Hypersensitivity Reactions to Dapsone: A Systematic Review.

Inhibition of angiogenesis as a new therapeutic target in the treatment of lepromatous leprosy.

Leprosy in china.

Generalized Serpiginous Eruption during Immunosuppressive Treatment for Leprosy Reactive Neuritis.

Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up.

Azathioprine as a steroid sparing agent in leprosy type 2 reactions: report of nine cases.

Chromoblastomycosis in a case of borderline lepromatous leprosy with recurrent type II lepra reaction.

Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers

Seagrass as a potential source of natural antioxidant and anti-inflammatory agents.

Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis

Advances and hurdles on the way toward a leprosy vaccine.